Is KURE a good investment?
KraneShares MSCI All China Health Care Index ETF (KURE) is a China-focused ETF. As of September 11, 2026, ETF Copilot scores KURE 4.1 out of 10 — highest on Valuation (8.1), lowest on Return (0.2). It trades at 22.7 times earnings, against its own median of 24.0. Its ten largest holdings are 56% of the fund.
Updated September 11, 2026
How is KURE rated? ETF Copilot scores KraneShares MSCI All China Health Care Index ETF (KURE) 4.1 out of 10
As of September 11, 2026, ETF Copilot scores KraneShares MSCI All China Health Care Index ETF (KURE) 4.1 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 4.1 / 10
- Growth: 5.4 / 10
- Valuation: 8.1 / 10
- Risk: 0.7 / 10
- Quality: 7.2 / 10
- Return: 0.2 / 10
KURE is ranked #5 of 10 in ETF Copilot's Rising Stars list.
What is KURE's expense ratio? 0.79% a year
As of September 11, 2026, KURE charges 0.79% a year, yields 1.06% and holds $108M in assets across 44 positions.
| Measure | KURE |
|---|---|
| Expense ratio | 0.79% |
| Dividend yield | 1.06% |
| Assets under management | $108M |
| Holdings | 44 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
What stands out in KURE's data
Chinese healthcare companies, from drugmakers to medical-device firms.
Earns more on its capital than the typical China-sector fund — a sign of real pricing power in its holdings.
Return on invested capital of 28.0% sits well above the category median of 18.5% and its own three-year median of 19.6%. It holds just 44 names.
A sector bet on China's healthcare industry, built for portfolios that want targeted growth exposure.
Why did KURE move this week? It fell 6.2% in the week to September 11, 2026 — Innovent Biologics and Wuxi Biologics drove it
KURE fell 6.2% in the week to September 11, 2026. The holdings that moved it most were Innovent Biologics (−8.8%), Wuxi Biologics (−7.3%) and Beone Medicines (−5.5%); Hangzhou Tigermed Consulting (+4.5%) pushed the other way.
Is KURE expensive right now? It trades at 22.7 times earnings, against its own median of 24.0
As of September 11, 2026, KURE is cheaper than 65% of its own 105 monthly readings since 2018 — 37 of those months were cheaper than today.
Trailing twelve-month, computed by ETF Copilot from the fund's holdings rather than quoted from a data provider, and rebuilt nightly.
What's inside KURE?
What's inside KURE: Size (Large 24%, Mid 67%, Small 9%); Geography (International 99%, US 1%).
What are KURE's top holdings? The ten largest are 56% of the fund
Innovent Biologics, Beone Medicines, Wuxi Biologics, Wuxi Apptec, Shenzhen Mindray Bio-Medic-A, Jiangsu Hengrui Pharmaceut, Akeso, Sino Biopharmaceutical and Cspc Pharmaceutical are KURE's largest holdings, in that order.
More concentrated than 58% of China ETFs.
Half of KURE's weight sits in its 9 largest positions, and once those weights are taken into account it behaves like 23 equally weighted holdings.
Cite this
ETF Copilot, “KraneShares MSCI All China Health Care Index ETF (KURE) scores and holdings analysis”, as of September 11, 2026.
https://etf-copilot.com/etf/kure
Register free to unlock KURE's price and what each holding weighs on ETF Copilot.
Register free →